Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alpha Ethyl 2 Oxo 1 Pyrrolidineacetamide
2. Alpha-ethyl-2-oxo-1-pyrrolidineacetamide
3. Etiracetam
4. Etiracetam, (r)-
5. Etiracetam, R Isomer
6. Etiracetam, R-isomer
7. Etiracetam, S Isomer
8. Etiracetam, S-isomer
9. Keppra
10. R-isomer Etiracetam
11. S-isomer Etiracetam
12. Ucb 6474
13. Ucb L059
14. Ucb L060
15. Ucb-6474
16. Ucb-l059
17. Ucb-l060
18. Ucb6474
19. Ucbl060
1. 102767-28-2
2. Keppra
3. (s)-2-(2-oxopyrrolidin-1-yl)butanamide
4. Keppra Xr
5. (2s)-2-(2-oxopyrrolidin-1-yl)butanamide
6. Ucb L059
7. Ucb-l 059
8. Matever
9. Ucb-l059
10. Levetiracetame
11. Levetiracetamum
12. Spritam
13. (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
14. Sib-s1
15. Elepsia
16. Levetiracetam Sun
17. (-)-(s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
18. Levetiracetam Teva
19. Ucb-22059
20. Levetiracetam Accord
21. Levetiracetam [inn]
22. Levetiracetam Actavis
23. Levetiracetam Hospira
24. N03ax14
25. Ucb 22059
26. Levetiracetamum [inn-latin]
27. Nsc-760119
28. 1-pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (alphas)-
29. Chebi:6437
30. Levetiracetam In Sodium Chloride
31. Agb-101
32. 44yrr34555
33. Levroxa
34. (s)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
35. Leviteracetam
36. Levipil
37. Torleva
38. Elepsia Xr
39. (s)-levetiracetam
40. Smr000466303
41. Keppra (tn)
42. Levesam 500
43. Etiracetam Levo-isomer
44. Sr-01000759400
45. Mfcd03265610
46. Unii-44yrr34555
47. E Keppra
48. Hsdb 7528
49. Levetiracetam [usan:usp:inn:ban]
50. E Keppra (tn)
51. Levetiracetam Solution
52. Levetiracetam- Bio-x
53. (s)-2-(2-oxo-1-pyrrolidinyl)butyramide
54. L-059
55. Levetiracetam [mi]
56. Levetiracetam [jan]
57. Chembl1286
58. Levetiracetam [hsdb]
59. Levetiracetam [usan]
60. Levetiracetam [vandf]
61. 1-pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (s)-
62. Mls000759403
63. Mls001424069
64. Mls006010215
65. Bidd:gt0242
66. Levetiracetam [mart.]
67. Schembl118843
68. Levetiracetam Ratiopharm
69. Levetiracetam [usp-rs]
70. Levetiracetam [who-dd]
71. Gtpl6826
72. Levetiracetam (jan/usp/inn)
73. Dtxsid9023207
74. Levetiracetam [ema Epar]
75. Levetiracetam Actavis Group
76. Levetiracetam, >=98% (hplc)
77. Levetiracetam, Analytical Standard
78. Hms2051d07
79. Hms2089l20
80. Hms2235i18
81. Hms3262h11
82. Hms3713p16
83. Hms3884o11
84. Pharmakon1600-01502265
85. Levetiracetam [ep Impurity]
86. Levetiracetam [orange Book]
87. Act02712
88. Albb-027275
89. Bcp11856
90. Hy-b0106
91. Zinc1547851
92. Levetiracetam [ep Monograph]
93. Levetiracetam [usp Impurity]
94. Tox21_500835
95. Bdbm50422542
96. Levetiracetam [usp Monograph]
97. Nsc760119
98. S1356
99. Stl388027
100. Levetiracetam 1.0 Mg/ml In Methanol
101. Akos015841981
102. Ac-1479
103. Ccg-100928
104. Cs-1854
105. Db01202
106. Ks-1176
107. Lp00835
108. Nc00178
109. Nsc 760119
110. Sdccgsbi-0633760.p001
111. (2s)-(2-oxopyrrolidin-1-yl)butyramide
112. Ncgc00186028-01
113. Ncgc00186028-13
114. Ncgc00261520-01
115. (s)-2-(2-oxopyrrolidin-1-yl)butyramide
116. Bl164623
117. (s)-2-(2-oxopyrrolidin-1-yl) Butyramide
118. Am20070676
119. L0234
120. Sw197558-3
121. C07841
122. D00709
123. Ab00639945-06
124. Ab00639945_07
125. Ab00639945_08
126. 767l282
127. A800616
128. (s)-2-(2-oxo-pyrrolidin-1-yl)-butyramide
129. Q-201292
130. Sr-01000759400-4
131. Sr-01000759400-5
132. (2s)-2-(2-oxopyrrolidin-1-yl)butanamide;levetiracetam
133. (-)-(s)-.alpha.-ethyl-2-oxo-1-pyrrolidineacetamide
134. 1-pyrrolidineacetamide, .alpha.-ethyl-2-oxo-, (.alpha.s)-
135. Levetiracetam, European Pharmacopoeia (ep) Reference Standard
136. Levetiracetam, United States Pharmacopeia (usp) Reference Standard
137. (-)-(s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide (2s)-2-(2-oxo-pyrrolidin-1-yl)butanamide
138. Levetiracetam Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
139. Levitiracetam, Pharmaceutical Secondary Standard; Certified Reference Material
| Molecular Weight | 170.21 g/mol |
|---|---|
| Molecular Formula | C8H14N2O2 |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 3 |
| Exact Mass | 170.105527694 g/mol |
| Monoisotopic Mass | 170.105527694 g/mol |
| Topological Polar Surface Area | 63.4 Ų |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 203 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Keppra |
| PubMed Health | Levetiracetam (By mouth) |
| Drug Classes | Anticonvulsant |
| Drug Label | KEPPRA is an antiepileptic drug available as 250 mg (blue), 500 mg (yellow), 750 mg (orange), and 1000 mg (white) tablets and as a clear, colorless, grape-flavored liquid (100 mg/mL) for oral administration.The chemical name of levetiracetam, a singl... |
| Active Ingredient | Levetiracetam |
| Dosage Form | Tablet; Injectable; Solution |
| Route | Iv (infusion); Oral |
| Strength | 250mg; 500mg; 500mg/5ml (100mg/ml); 100mg/ml; 750mg; 1gm |
| Market Status | Prescription |
| Company | Ucb |
| 2 of 6 | |
|---|---|
| Drug Name | Keppra xr |
| PubMed Health | Levetiracetam |
| Drug Classes | Anticonvulsant |
| Drug Label | KEPPRA XR is an antiepileptic drug available as 500 mg and 750 mg (white) extended-release tablets for oral administration.The chemical name of levetiracetam, a single enantiomer, is (-)-(S)--ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formu... |
| Active Ingredient | Levetiracetam |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 500mg; 750mg |
| Market Status | Prescription |
| Company | Ucb |
| 3 of 6 | |
|---|---|
| Drug Name | Levetiracetam |
| PubMed Health | Levetiracetam |
| Drug Classes | Anticonvulsant |
| Drug Label | Levetiracetam is an antiepileptic drug available as 250 mg (blue), 500 mg (yellow) and 750 mg (orange) tablets.The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-acetamide, its molecular formula is C8H14N2O2 and its molecular weight... |
| Active Ingredient | Levetiracetam |
| Dosage Form | Tablet, extended release; Tablet; Injectable; Solution |
| Route | oral; Iv (infusion); Oral |
| Strength | 250mg; 500mg/5ml(100mg/ml); 1000mg; 500mg; 500mg/ml (100mg/ml); 500mg/5ml (100mg/ml); 100mg/ml; 750mg; 1gm |
| Market Status | Tentative Approval; Prescription |
| Company | Vintage Pharms; Mylan Pharms; Anchen Pharms; Amneal Pharms; Wockhardt; Silarx; Hospira; Breckenridge Pharm; Actavis Labs Fl; X Gen Pharms; Methapharm; Apotex; Lotus Pharm; Accord Hlthcare; Hetero Labs Ltd Iii; Hikma Farmaceutica; Sun Pharm Inds; Aurobindo |
| 4 of 6 | |
|---|---|
| Drug Name | Keppra |
| PubMed Health | Levetiracetam (By mouth) |
| Drug Classes | Anticonvulsant |
| Drug Label | KEPPRA is an antiepileptic drug available as 250 mg (blue), 500 mg (yellow), 750 mg (orange), and 1000 mg (white) tablets and as a clear, colorless, grape-flavored liquid (100 mg/mL) for oral administration.The chemical name of levetiracetam, a singl... |
| Active Ingredient | Levetiracetam |
| Dosage Form | Tablet; Injectable; Solution |
| Route | Iv (infusion); Oral |
| Strength | 250mg; 500mg; 500mg/5ml (100mg/ml); 100mg/ml; 750mg; 1gm |
| Market Status | Prescription |
| Company | Ucb |
| 5 of 6 | |
|---|---|
| Drug Name | Keppra xr |
| PubMed Health | Levetiracetam |
| Drug Classes | Anticonvulsant |
| Drug Label | KEPPRA XR is an antiepileptic drug available as 500 mg and 750 mg (white) extended-release tablets for oral administration.The chemical name of levetiracetam, a single enantiomer, is (-)-(S)--ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formu... |
| Active Ingredient | Levetiracetam |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 500mg; 750mg |
| Market Status | Prescription |
| Company | Ucb |
| 6 of 6 | |
|---|---|
| Drug Name | Levetiracetam |
| PubMed Health | Levetiracetam |
| Drug Classes | Anticonvulsant |
| Drug Label | Levetiracetam is an antiepileptic drug available as 250 mg (blue), 500 mg (yellow) and 750 mg (orange) tablets.The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-acetamide, its molecular formula is C8H14N2O2 and its molecular weight... |
| Active Ingredient | Levetiracetam |
| Dosage Form | Tablet, extended release; Tablet; Injectable; Solution |
| Route | oral; Iv (infusion); Oral |
| Strength | 250mg; 500mg/5ml(100mg/ml); 1000mg; 500mg; 500mg/ml (100mg/ml); 500mg/5ml (100mg/ml); 100mg/ml; 750mg; 1gm |
| Market Status | Tentative Approval; Prescription |
| Company | Vintage Pharms; Mylan Pharms; Anchen Pharms; Amneal Pharms; Wockhardt; Silarx; Hospira; Breckenridge Pharm; Actavis Labs Fl; X Gen Pharms; Methapharm; Apotex; Lotus Pharm; Accord Hlthcare; Hetero Labs Ltd Iii; Hikma Farmaceutica; Sun Pharm Inds; Aurobindo |
Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. /included in US product labe/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 1815
Adverse neuropsychiatric effects reported during levetiracetam treatment are classified into 3 categories: somnolence and fatigue, coordination difficulties, and behavioral changes. In controlled studies, 14.8% of patients who received levetiracetam experienced somnolence compared with 8.4% of placebo-treated patients, and about 3% of levetiracetam-treated patients discontinued treatment due to somnolence. About 14.7% of patients who received levetiracetam experienced asthenia compared with 9.1% of placebo-treated patients, and 0.8% of levetiracetam-treated patients discontinued treatment due to asthenia. Coordination difficulties were experienced by 3.4% of levetiracetam patients compared with 1.6% of placebo-treated patients. Somnolence, asthenia, and coordination difficulties occurred most frequently within the first 4 weeks of treatment. Psychotic manifestations and hallucinations were reported rarely in patients receiving levetiracetam in clinical studies. Other behavioral symptoms (e.g., agitation, hostility, anxiety, apathy, emotional lability, depersonalization, depression, aggression, anger, irritability) occurred in 13.3% of levetiracetam-treated patients in clinical studies compared with 6.2% of placebo patients, and 1.7% of levetiracetam-treated patients discontinued treatment because of these events.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2240
Because of the possibility of increased seizure frequency, anticonvulsant drugs, including levetiracetam, should not be discontinued suddenly. Levetiracetam should be withdrawn gradually by reducing the dosage by 1g daily at 2-week intervals.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2240
Adverse effects occurring in 1% or more of patients receiving levetiracetam and more frequently than placebo include somnolence, asthenia, headache, infection, dizziness, pain, pharyngitis, depression, nervousness, rhinitis, anorexia, ataxia, vertigo, amnesia, anxiety, emotional lability, hostility, paresthesia, increased cough, sinusitis, and diplopia and were reported in clinical studies in which levetiracetam was administered in conjunction with other anticonvulsants. Asthenia, somnolence, and dizziness occurred predominantly during the initial 4 weeks of treatment.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2240
Minor decreases in total mean erythrocyte count, mean hemoglobin, and mean hematocrit have been reported. Leukopenia, neutropenia, pancytopenia (with myelosuppression in some cases), and thrombocytopenia also have been observed, although a causal relationship to the drug has not been established.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 2240
For more Drug Warnings (Complete) data for LEVETIRACETAM (12 total), please visit the HSDB record page.
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older. Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.
Levetiracetam Actavis is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Levetiracetam Actavis is indicated as adjunctive therapy:
- in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Levetiracetam Actavis Group is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Levetiracetam Actavis Group is indicated as adjunctive therapy:
- in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
Levetiracetam Hospira is indicated as adjunctive therapy
- in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy .
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy .
Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible.
Levetiracetam ratiopharm is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Levetiracetam ratiopharm is indicated as adjunctive therapy:
- in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Levetiracetam is indicated as adjunctive therapy:
- in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Levetiracetam Teva is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
Levetiracetam Teva is indicated as adjunctive therapy:
- in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy;
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Keppra is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Keppra is indicated as adjunctive therapy:
- in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Matever is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Matever is indicated as adjunctive therapy:
- in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Levetiracetam Sun is indicated as adjunctive therapy:
- in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.
Levetiracetam appears to prevent seizure activity via the selective inhibition of hypersynchronized epileptiform burst firing without affecting normal neuronal transmission, though the exact mechanism through which this occurs is unclear. The therapeutic index of levetiracetam is wide, making it relatively unique amongst other anti-epileptic medications. Anti-epileptic drugs, including levetiracetam, may increase the risk of suicidal ideation or behaviour - patients taking levetiracetam should be monitored for the emergence or worsening of depressive symptoms, suicidal ideation, and behavioural abnormalities.
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Nootropic Agents
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)
N03AX14
N03AX14
N03AX14
N03AX14
N03AX14
N03AX14
N03AX14
N03AX14
N03AX14
N03AX14
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AX - Other antiepileptics
N03AX14 - Levetiracetam
Absorption
Levetiracetam is rapidly and nearly completely absorbed following oral administration, with a reported absolute oral bioavailability of essentially 100%. Tmax is approximately 1.3 hours after dosing, and Cmax is 31 g/mL following a single 1000mg dose and 43 g/mL following repeated dosing. Co-administration of levetiracetam with food delays Tmax by approximately 1.5 hours and decreases Cmax by 20%.
Route of Elimination
Approximately 66% of the administered dose of levetiracetam is excreted in the urine as unchanged drug, while only 0.3% of the total dose is excreted via the feces. The primary inactive metabolite of levetiracetam, L057, is also found in the urine as approximately 24% of the administered dose.
Volume of Distribution
The volume of distribution of levetiracetam is approximately 0.5 to 0.7 L/kg.
Clearance
The total plasma clearance of levetiracetam is 0.96 mL/min/kg, with renal clearance comprising 0.6 mL/min/kg. The primary inactive metabolite of levetiracetam, L057, has a renal clearance of 4 mL/min/kg. Given the relatively high proportion of drug undergoing renal clearance, overall clearance of levetiracetam is reduced in patients with renal impairment.
Absorption of levetiracetam is rapid, with peak plasma concentrations occurring in about an hour following oral administration in fasted subjects. The oral bioavailability of levetiracetam tablets is 100% and the tablets and oral solution are bioequivalent in rate and extent of absorption. Food does not affect the extent of absorption of levetiracetam but it decreases C max by 20% and delays T max by 1.5 hours.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3315
The pharmacokinetics of levetiracetam are linear over the dose range of 500-5000 mg. Steady state is achieved after 2 days of multiple twice-daily dosing.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3315
Levetiracetam is not significantly protein-bound (<10% bound) and its volume of distribution is close to the volume of intracellular and extracellular water.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3315
Levetiracetam C max and AUC were 20% higher in women (N=11) compared to men (N=12). However, clearances adjusted for body weight were comparable.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3315
For more Absorption, Distribution and Excretion (Complete) data for LEVETIRACETAM (12 total), please visit the HSDB record page.
Levetiracetam is minimally metabolized within the body - the major metabolic pathway appears to be the enzymatic hydrolysis of its acetamide group which produces an inactive carboxylic acid metabolite, L057, which accounts for approximately 24% of the total administered dose. The specific enzyme(s) responsible for this reaction are unclear, but this pathway is known to be independent of hepatic CYP enzymes and has been proposed to be driven primarily by type B esterases in the blood and other tissues. Two minor metabolites involving modifications to the pyrrolidone ring have been identified, one involving hydroxylation of the ring (constituting 1.6% of the total dose) and the other involving opening of the ring structure (constituting 0.9% of the total dose).
Levetiracetam is not extensively metabolized in humans. The major metabolic pathway is the enzymatic hydrolysis of the acetamide group, which produces the carboxylic acid metabolite, ucb L057 (24% of dose) and is not dependent on any liver cytochrome P450 isoenzymes. The major metabolite is inactive in animal seizure models. Two minor metabolites were identified as the product of hydroxylation of the 2-oxo-pyrrolidine ring (2% of dose) and opening of the 2-oxo-pyrrolidine ring in position 5 (1% of dose). There is no enantiomeric interconversion of levetiracetam or its major metabolite.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3315
The plasma half-life of levetiracetam is 6-8 hours and is not affected by dose or repeat administration. Half-life is increased in the elderly (by about 40%) and those with renal impairment.
... The plasma elimination half-life of the unchanged drug varied between 7.4 hr and 7.9 hr. ...
PMID:14530892 Strolin-Benedetti M et al; Eur J Clin Pharmacol 59 (8-9): 621-30 (2003)
Levetiracetam plasma half-life in adults is 7 +/-1 hour and is unaffected by either dose or repeated administration.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3315
The exact mechanism through which levetiracetam exerts its anti-epileptic effects is unclear, but is thought to be unique amongst other anti-epileptic medications. Current knowledge suggests that levetiracetams binding to synaptic vesicle protein 2A (SV2A) is a key driver of its action. SV2A is a membrane-bound protein that is found on synaptic vesicles and is ubiquitous throughout the CNS - it appears to play a role in vesicle exocytosis and in the modulation of synaptic transmission by increasing the available amount of secretory vesicles available for neurotransmission. Stimulation of pre-synaptic SV2A by levetiracetam may inhibit neurotransmitter release, but this action does not appear to affect normal neurotransmission. This has led to the suggestion that levetiracetam exclusively modulates the function of SV2A only under pathophysiological conditions. Levetiracetam and related analogues showed a correlation between affinity for SV2A and anti-epileptic potency, further suggesting that action at this site contributes to the anti-epileptic activity of the drug. Levetiracetam has also been shown to indirectly affect GABAergic neurotransmission (despite having no direct effect on GABAergic or glutamatergic receptors) and modulate ionic currents. Similarly, levetiracetam has been shown in vitro to inhibit N-type calcium channels. How, or even if, these actions are implicated in its anti-epileptic action have yet to be elucidated.
The precise mechanism by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Protection was observed, however, against secondarily generalized activity from focal seizures induced by pilocarpine and kainic acid, two chemoconvulsants that induce seizures that mimic some features of human complex partial seizures with secondary generalization. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human complex partial seizures, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human epilepsy is uncertain.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3314
In vitro and in vivo recordings of epileptiform activity from the hippocampus have shown that levetiracetam inhibits burst firing without affecting normal neuronal excitability, suggesting that levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3314
Levetiracetam at concentrations of up to 10 muM did not demonstrate binding affinity for a variety of known receptors, such as those associated with benzodiazepines, GABA (gammaaminobutyric acid), glycine, NMDA (N-methyl-D-aspartate), re-uptake sites, and second messenger systems. Furthermore, in vitro studies have failed to find an effect of levetiracetam on neuronal voltage-gated sodium or T-type calcium currents and levetiracetam does not appear to directly facilitate GABAergic neurotransmission. However, in vitro studies have demonstrated that levetiractem opposes the activity of negative modulators of GABA- and glycine-gated currents and partially inhibits N-type calcium currents in neuronal cells.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3314
A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3315
For more Mechanism of Action (Complete) data for LEVETIRACETAM (6 total), please visit the HSDB record page.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 1GM
USFDA APPLICATION NUMBER - 21035
DOSAGE - TABLET;ORAL - 250MG
USFDA APPLICATION NUMBER - 21035
DOSAGE - TABLET;ORAL - 500MG
USFDA APPLICATION NUMBER - 21035
DOSAGE - TABLET;ORAL - 750MG
USFDA APPLICATION NUMBER - 21035
DOSAGE - INJECTABLE;INTRAVENOUS - 500MG/5ML (...DOSAGE - INJECTABLE;INTRAVENOUS - 500MG/5ML (100MG/ML)
USFDA APPLICATION NUMBER - 21872
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 500M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 500MG
USFDA APPLICATION NUMBER - 22285
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 750M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 750MG
USFDA APPLICATION NUMBER - 22285
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Avesta Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Bioplus Life Sciences
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Huzhou Sunflower Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vertellus
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Thickeners and Stabilizers
Disintegrants & Superdisintegrants
Taste Masking
Film Formers & Plasticizers
Controlled & Modified Release
Solubilizers
Granulation
Topical
Parenteral
Lubricants & Glidants
Chewable & Orodispersible Aids
Co-Processed Excipients
Emulsifying Agents
Surfactant & Foaming Agents
Rheology Modifiers
API Stability Enhancers
Empty Capsules
Coloring Agents
Vegetarian Capsules
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
77
PharmaCompass offers a list of Levetiracetam API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Levetiracetam manufacturer or Levetiracetam supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Levetiracetam manufacturer or Levetiracetam supplier.
PharmaCompass also assists you with knowing the Levetiracetam API Price utilized in the formulation of products. Levetiracetam API Price is not always fixed or binding as the Levetiracetam Price is obtained through a variety of data sources. The Levetiracetam Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Keppra XR manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Keppra XR, including repackagers and relabelers. The FDA regulates Keppra XR manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Keppra XR API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Keppra XR manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Keppra XR supplier is an individual or a company that provides Keppra XR active pharmaceutical ingredient (API) or Keppra XR finished formulations upon request. The Keppra XR suppliers may include Keppra XR API manufacturers, exporters, distributors and traders.
click here to find a list of Keppra XR suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Keppra XR DMF (Drug Master File) is a document detailing the whole manufacturing process of Keppra XR active pharmaceutical ingredient (API) in detail. Different forms of Keppra XR DMFs exist exist since differing nations have different regulations, such as Keppra XR USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Keppra XR DMF submitted to regulatory agencies in the US is known as a USDMF. Keppra XR USDMF includes data on Keppra XR's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Keppra XR USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Keppra XR suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Keppra XR Drug Master File in Japan (Keppra XR JDMF) empowers Keppra XR API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Keppra XR JDMF during the approval evaluation for pharmaceutical products. At the time of Keppra XR JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Keppra XR suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Keppra XR Drug Master File in Korea (Keppra XR KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Keppra XR. The MFDS reviews the Keppra XR KDMF as part of the drug registration process and uses the information provided in the Keppra XR KDMF to evaluate the safety and efficacy of the drug.
After submitting a Keppra XR KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Keppra XR API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Keppra XR suppliers with KDMF on PharmaCompass.
A Keppra XR CEP of the European Pharmacopoeia monograph is often referred to as a Keppra XR Certificate of Suitability (COS). The purpose of a Keppra XR CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Keppra XR EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Keppra XR to their clients by showing that a Keppra XR CEP has been issued for it. The manufacturer submits a Keppra XR CEP (COS) as part of the market authorization procedure, and it takes on the role of a Keppra XR CEP holder for the record. Additionally, the data presented in the Keppra XR CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Keppra XR DMF.
A Keppra XR CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Keppra XR CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Keppra XR suppliers with CEP (COS) on PharmaCompass.
A Keppra XR written confirmation (Keppra XR WC) is an official document issued by a regulatory agency to a Keppra XR manufacturer, verifying that the manufacturing facility of a Keppra XR active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Keppra XR APIs or Keppra XR finished pharmaceutical products to another nation, regulatory agencies frequently require a Keppra XR WC (written confirmation) as part of the regulatory process.
click here to find a list of Keppra XR suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Keppra XR as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Keppra XR API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Keppra XR as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Keppra XR and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Keppra XR NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Keppra XR suppliers with NDC on PharmaCompass.
Keppra XR Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Keppra XR GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Keppra XR GMP manufacturer or Keppra XR GMP API supplier for your needs.
A Keppra XR CoA (Certificate of Analysis) is a formal document that attests to Keppra XR's compliance with Keppra XR specifications and serves as a tool for batch-level quality control.
Keppra XR CoA mostly includes findings from lab analyses of a specific batch. For each Keppra XR CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Keppra XR may be tested according to a variety of international standards, such as European Pharmacopoeia (Keppra XR EP), Keppra XR JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Keppra XR USP).
